by 
Cancer Metabolism Based Therapeutics seek to target abnormal metabolic processes that occur in cancer cells. These include targeting glycolysis and glutaminolysis to disrupt cancer cell proliferation and survival. Such therapies have fewer side effects compared to traditional chemotherapy while achieving comparable efficacy. The global Cancer Metabolism Based Therapeutics Market is estimated to be valued at US$ 210.2 billion in 2023 and is expected to exhibit a CAGR of 95.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Emerging therapies targeting cancer metabolism have shown promise in clinical trials and are driving significant growth in this market. One such trend is targeting tumor dependence on glutamine oxidation using glutaminase inhibitors. Blocking glutamine conversion to glutamate disrupts redox homeostasis in cancer cells, halting their proliferation. Many pharmaceutical companies are developing glutaminase inhibitors for leukemias and lymphomas, expanding therapeutic options for patients. This focus on interrupting glutamine metabolism in cancer is a major trend propelling the cancer metabolism based therapeutics market.
SWOT Analysis
Strength: Metabolism-based cancer therapeutics have the potential to target metabolic weaknesses in cancer cells specifically. This provides an opportunity for more precise targeting with fewer side effects compared to traditional chemotherapy.
Weakness: The metabolism of cancer cells can vary significantly between different cancer types and even between tumors of the same cancer type in different patients. This variability poses challenges for developing single therapies that will be broadly effective.
Opportunity: Advances in understanding cancer metabolism open up new pathways that were previously unknown and provide many novel targets for drug development. The metabolism-based approach is still in its early stages with significant room for innovation and discovery.
Threats: Developing drugs that safely interfere with fundamental metabolic processes in the body requires extensive research and testing to avoid toxicity. Competitors may find alternative targets that are more straightforward to develop into therapies.
Key Takeaways
The global cancer metabolism based therapeutics market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is anticipated to reach US$ 210.2 billion by 2024, growing at an accelerated rate of 95% CAGR.
Regional analysis shows that North America currently dominates the market, owing to advanced research capabilities and increasing prevalence of cancers in the region. However, Asia Pacific is expected to rise as the fastest growing market due to rising healthcare investment and expanding patient population.
Key players operating in the cancer metabolism based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca. These companies are focusing on developing novel targeted therapies and conducting clinical trials to evaluate safety and efficacy in various cancer indications. Partnerships and licensing deals between pharmaceutical giants and biotech startups are also gaining momentum.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
